Avacopan for ANCA-associated Vasculitis

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting Phase 4 Interventional Study
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
300 (estimated)
Sponsor
Amgen · Industry
Who this trial is looking for

This trial is looking for people with a specific type of vasculitis called ANCA-associated vasculitis. Participants will be monitored to assess the long-term safety of the medication avacopan.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old.
  • I have been diagnosed with ANCA-associated vasculitis.
  • I need treatment with cyclophosphamide or rituximab.
  • I have tested positive for certain antibodies.
  • I have a specific score indicating the activity of my condition.
  • My kidney function is adequate.
  • I have provided consent to participate.

You may not be able to join if

  • I have a serious lung problem requiring ventilation support.
  • I have another autoimmune disease.
  • I have received dialysis or plasma exchange in the last 16 weeks.
  • I have had a kidney transplant.
  • I have had cancer in the last 5 years (except certain skin cancers).
  • I have an active infection with hepatitis B, hepatitis C, or HIV.
  • I have had a serious infection or significant cardiovascular event recently.
  • I have been taking high doses of glucocorticoids for too long.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participants has provided informed consent before initiation of any study-specific activities/procedures. * Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis, consistent with Chapel-Hill Consensus Conference definitions (Jennette et al,…
Contacts

Amgen Call Center

866-572-6436

medinfo@amgen.com

CONTACT